Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like Meet The Top 5 Drug-Delivery Companies With Their Latest Projects and Products October 26, 2017 FDA Berates Lupin for Repeatedly Making Pills That Don't Meet Quality Standards November 15, 2017 PENTAX Medical Launches New Slim Linear Ultrasound Endoscope August 8, 2017
